Oct 2026· Nuclear Medicine and Biology· Vol 162-163, pp.
109840
· 0 citations· 20 references
Medicine
TL;DR
This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer.
Abstract
Background
Advanced lung cancer remains a major therapeutic challenge, with limited efficacy of single-agent therapies. Fibroblast activation protein-targeted radioligand therapy (FAP-RLT) induces tumor-specific DNA damage, which may prime the cGAS-STING innate immune pathway. We explored whether [177Lu]Lu-FAP-2286 (FAP-RLT) synergizes with the STING agonist diABZI to enhance antitumor immunity in FAP-positive lung cancer.
Methods
An immunocompetent C57BL/6 Lewis lung carcinoma model with stable FAP overexpression, designated LLC-FAP, was established. Tumor targeting of [177Lu]Lu-FAP-2286 was evaluated by ex vivo biodistribution. Mice were treated with PBS, [177Lu]Lu-FAP-2286 alone, diABZI alone, or combination therapy. Antitumor efficacy was assessed by tumor volume measurement and survival analysis. Mechanistic studies included immunohistochemistry of IFN-β expression, CD8+ T-cell infiltration and tumor cell apoptosis biomarkers.
Results
[177Lu]Lu-FAP-2286 showed excellent tumor targeting (9.8 ± 1.3%ID/g at 4 h post-injection) and induced DNA damage (γ-H2AX: +318.9%)/STING upregulation (H-score: +52.0%). The combination therapy yielded superior antitumor activity, resulting in a 50.3 ± 14.8% tumor volume reduction at short-term efficacy evaluation and a prolonged median survival of 45.6 ± 6.3 days, compared with 34.1 ± 4.3 days for the STINGa monotherapy group (P < 0.001)and 22.6 ± 2.3 days for the [177Lu]Lu-FAP-2286 monotherapy group (P < 0.001). Mechanistically, the combination significantly enhanced CD8+ T-cell infiltration in tumors compared with the STINGa monotherapy group (24.5 ± 1.4% vs. 9.9 ± 0.1% of CD45+ cells, P = 0.003) and the [177Lu]Lu-FAP-2286 monotherapy group (24.5 ± 1.4% vs.7.5 ± 0.4% of CD45+ cells, P < 0.001). This effect was accompanied by elevated IFN-β expression and promoted tumor cell apoptosis. No overt treatment-related toxicity was observed in major organs.
Conclusions
[177Lu]Lu-FAP-2286 acts as a potent immune sensitizer for STING agonist therapy. This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer.
Background/Objectives: During prostate cancer progression, downregulation or loss of prostate-specific membrane antigen (PSMA) expression, together with interlesional heterogeneity, may limit the efficacy of PSMA-targeted radioligand therapy. Fibroblast activation protein (FAP), expressed mainly by activated cancer-ass...
R. Xue, Ya-Chao Liu, Xin-Lin Wang et al.· Pharmaceuticals· 0 citations
Fibroblast activation protein (FAP) is an attractive target for radiotheranostic development because of its abundant expression in tumor-associated fibroblasts and limited distribution in normal tissues. Here, we developed FAP-Man, a mannosylated FAP-targeted radioglycopeptide based on the FAP-2286 scaffold, to optimiz...
Miao-Miao Song, En-Tao Liu, Rui Cao et al.· Journal of Medicinal Chemist...· 0 citations
Triple-negative breast cancer (TNBC) has limited targeted treatment options and is strongly influenced by stromal biology. This study evaluated [
177
Lu]Lu-FAPI for fibroblast activation protein-alpha (FAP)-directed tumor microenvironment targeting in TNBC models.
[
177
Lu]Lu-FAPI was assessed usin...
Zhi-Hua Tang, Lu-Shan Yu, Ke Zhang· Frontiers in Oncology· 0 citations
PURPOSE
HER2-positive breast cancer requires targeted therapies that overcome resistance and desmoplastic barriers. This study aimed to develop and biologically evaluate a 177Lu-labeled Inetetamab conjugate (177Lu-Inetetamab) with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy.
METH...
Jian-Ping Zheng, Yu Zhang, Qing-Qing Li et al.· Bioorganic chemistry (Print)· 0 citations
Purpose Hepatocellular carcinoma (HCC) remains a major clinical challenge due to its high recurrence rate, poor response to systemic therapies, and unfavorable prognosis. Human epidermal growth factor receptor 3 (HER3) has emerged as a clinically relevant molecular target in HCC. Seribantumab is a fully human IgG2 mono...
Jiao-Jiao Li, Xiao Yang, Aodungerile Li et al.· Drug Design, Development and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.